|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1270 - 0.1300|
|52 Week Range||0.0900 - 0.3300|
|Beta (5Y Monthly)||0.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As reported in the Journal of Biological Control, volume 31, viral diseases can result in total annual silk production losses of as much as 32%. Kraig Labs has developed its first immune-enhancing genetic insert, designed to create disease-resistant silkworms. The Company is now ready for its first round of transgenic creation and resistance testing.
"Kraig Labs has been blessed with loyal shareholders, and we expect that moving to Nasdaq will raise the Company's visibility and expand our shareholder family." The Company’s application for uplisting, to the Nasdaq Capital Market, is subject to approval based on the ability to meet Nasdaq requirements.
During this meeting, management briefed the board on the Company’s plans for 2020 expansion and growth. The Company’s expansion of its Board of Directors is intended to strengthen its corporate governance and to directly address the requirements for listing on a national exchange. The board will help the Company navigate what management expects to be a period of significant growth.